ArticleVaccine2011
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 81 citations in OpenAlex.
- Infusion of neutralization into Lassa vaccine design.Trends in immunology · 2025Review
- Current perspectives on vaccines and therapeutics for Lassa Fever.Virology journal · 2024Review
- A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.NPJ vaccines · 2024Article
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.Journal of virology · 2024Article
- Vaccine Candidates against Arenavirus Infections.Vaccines · 2023Review
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines.Vaccines · 2022Review
- Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.EBioMedicine · 2022Article
- Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice.Frontiers in tropical diseases · 2022Article
- Article
- Advances in the design and development of SARS-CoV-2 vaccines.Military Medical Research · 2021Review
- Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.Virulence · 2021Review
- Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.Vaccines · 2021Review
- Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.Vaccines · 2020Review
- A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.mBio · 2020Article
- A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.mBio · 2020Article
- Vaccine platforms for the prevention of Lassa fever.Immunology letters · 2019Review
- Emerging viruses and current strategies for vaccine intervention.Clinical and experimental immunology · 2019Review
- Lassa virus diversity and feasibility for universal prophylactic vaccine.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Yellow Fever (YF) and Lassa Fever (LF) are two prevalent hemorrhagic fevers co-circulating in West Africa and responsible for thousands of deaths annually. The YF vaccine 17D has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) or their subunits, GP1 (attachment glycoprotein) and GP2 (fusion glycoprotein). Cloning shorter inserts, LASV-GP1 and -GP2, between YF17D E and NS1 genes enhanced genetic stability of recombinant viruses, YF17D/LASV-GP1 and -GP2, in comparison with YF17D/LASV-GPC recombinant. The recombinant viruses were replication competent and properly processed YF proteins and LASV GP antigens in infected cells. YF17D/LASV-GP1 and -GP2 induced specific CD8+ T cell responses in mice and protected strain 13 guinea pigs against fatal LF. Unlike immunization with live attenuated reassortant vaccine ML29, immunization with YF17D/LASV-GP1 and -GP2 did not provide sterilizing immunity. This study demonstrates the feasibility of YF17D-based vaccine to control LF in West Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.